{"id":"https://openalex.org/W2014417704","doi":"https://doi.org/10.1016/j.ejca.2014.03.012","title":"Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma","display_name":"Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma","publication_year":2014,"publication_date":"2014-04-23","ids":{"openalex":"https://openalex.org/W2014417704","doi":"https://doi.org/10.1016/j.ejca.2014.03.012","mag":"2014417704","pmid":"https://pubmed.ncbi.nlm.nih.gov/24768571"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejca.2014.03.012","doi":"https://doi.org/10.1016/j.ejca.2014.03.012","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2014.03.012","pdf_url":"http://www.ejcancer.com/article/S095980491400255X/pdf","source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"http://www.ejcancer.com/article/S095980491400255X/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020353650","display_name":"Sylvie N\u00e9grier","orcid":"https://orcid.org/0000-0002-0984-8505","observed_orcids":["https://orcid.org/0000-0002-0984-8505"]},"institutions":[{"id":"https://openalex.org/I203339264","display_name":"Universit\u00e9 de Lyon","ror":"https://ror.org/01rk35k63","country_code":"FR","type":"education","lineage":["https://openalex.org/I203339264"]},{"id":"https://openalex.org/I4210105738","display_name":"Centre L\u00e9on B\u00e9rard","ror":"https://ror.org/01cmnjq37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210105738"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"S. N\u00e9grier","raw_affiliation_strings":["Universit\u00e9 de Lyon, Centre L\u00e9on B\u00e9rard, 28, rue Laennec, F-69373 Lyon Cedex 08, France. Electronic address: sylvie.negrier@lyon.unicancer.fr","Universit\u00e9 de Lyon, Centre L\u00e9on B\u00e9rard, 28, rue Laennec, F-69373 Lyon Cedex 08, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e9 de Lyon, Centre L\u00e9on B\u00e9rard, 28, rue Laennec, F-69373 Lyon Cedex 08, France. Electronic address: sylvie.negrier@lyon.unicancer.fr","institution_ids":["https://openalex.org/I203339264","https://openalex.org/I4210105738"]},{"raw_affiliation_string":"Universit\u00e9 de Lyon, Centre L\u00e9on B\u00e9rard, 28, rue Laennec, F-69373 Lyon Cedex 08, France","institution_ids":["https://openalex.org/I203339264","https://openalex.org/I4210105738"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031955903","display_name":"Andrew G. Bushmakin","orcid":"https://orcid.org/0000-0002-0082-6545","observed_orcids":["https://orcid.org/0000-0002-0082-6545"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A.G. Bushmakin","raw_affiliation_strings":["Statistics, Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Statistics, Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091669022","display_name":"Joseph C. Cappelleri","orcid":"https://orcid.org/0000-0001-9586-0748","observed_orcids":["https://orcid.org/0000-0001-9586-0748"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J.C. Cappelleri","raw_affiliation_strings":["Statistics, Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Statistics, Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064227174","display_name":"Beata Korytowsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. Korytowsky","raw_affiliation_strings":["Global Health Economics and Outcomes Research, Pfizer Oncology, 235 E 42nd St, New York, NY 10017, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Economics and Outcomes Research, Pfizer Oncology, 235 E 42nd St, New York, NY 10017, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042175259","display_name":"Rickard Sandin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092030","display_name":"Pfizer (Sweden)","ror":"https://ror.org/00kkwkq76","country_code":"SE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210092030"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"R. Sandin","raw_affiliation_strings":["Global Health Economics and Outcomes Research, Pfizer Oncology, Vetenskapsv\u00e4gen 10, Sollentuna 10191, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Economics and Outcomes Research, Pfizer Oncology, Vetenskapsv\u00e4gen 10, Sollentuna 10191, Sweden","institution_ids":["https://openalex.org/I4210092030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026321359","display_name":"Claudie Charbonneau","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118061","display_name":"Pfizer (France)","ror":"https://ror.org/02c9yny10","country_code":"FR","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210118061"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"C. Charbonneau","raw_affiliation_strings":["Global Outcomes Research, Specialty Care BU, Pfizer P.I.O., 23-25, avenue du Dr. Lannelongue, 75014 Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Outcomes Research, Specialty Care BU, Pfizer P.I.O., 23-25, avenue du Dr. Lannelongue, 75014 Paris, France","institution_ids":["https://openalex.org/I4210118061"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028789952","display_name":"Marc Dror Michaelson","orcid":"https://orcid.org/0000-0001-9249-6338","observed_orcids":["https://orcid.org/0000-0001-9249-6338"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.D. Michaelson","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, 55 Fruit Street, YAW 7, Boston, MA 02114, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, 55 Fruit Street, YAW 7, Boston, MA 02114, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050649350","display_name":"Robert A. Figlin","orcid":"https://orcid.org/0000-0002-6323-6075","observed_orcids":["https://orcid.org/0000-0002-6323-6075"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R.A. Figlin","raw_affiliation_strings":["Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Saperstein Critical Care Tower, 1S28, Los Angeles, CA 90048, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Saperstein Critical Care Tower, 1S28, Los Angeles, CA 90048, USA","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059063118","display_name":"Robert John Motzer","orcid":"https://orcid.org/0000-0001-6925-2327","observed_orcids":["https://orcid.org/0000-0001-6925-2327"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R.J. Motzer","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5020353650"],"corresponding_institution_ids":["https://openalex.org/I203339264","https://openalex.org/I4210105738"],"apc_list":{"value":4270,"currency":"USD","value_usd":4270},"apc_paid":{"value":4270,"currency":"USD","value_usd":4270},"fwci":2.669,"has_fulltext":true,"cited_by_count":20,"citation_normalized_percentile":{"value":0.89690459,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"50","issue":"10","first_page":"1766","last_page":"1771"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.8446999788284302,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.8446999788284302,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.13650000095367432,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.003000000026077032,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8489999771118164},{"id":"https://openalex.org/keywords/surrogate-endpoints","display_name":"surrogate endpoints","score":0.847000002861023},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9959999918937683},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/sunitinib","display_name":"sunitinib","score":0.972000002861023},{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.9980000257492065},{"id":"https://openalex.org/keywords/post-progression-survival","display_name":"post-progression survival","score":0.8930000066757202},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7749999761581421},{"id":"https://openalex.org/keywords/weibull-model","display_name":"Weibull model","score":0.7300000190734863},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.714842677116394},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6625016331672668},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.6548606753349304},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.6462892889976501},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.6378995776176453},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6241042613983154},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5917298793792725},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.4984779357910156},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4903111755847931},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.4859146177768707},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.43965500593185425},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.4235900640487671},{"id":"https://openalex.org/C2779466056","wikidata":"https://www.wikidata.org/wiki/Q107630651","display_name":"Time point","level":2,"score":0.41908785700798035},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.36550137400627136},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.1773788034915924},{"id":"https://openalex.org/C107038049","wikidata":"https://www.wikidata.org/wiki/Q35986","display_name":"Aesthetics","level":1,"score":0.0},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.0},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000077210","descriptor_name":"Sunitinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015337","descriptor_name":"Multicenter Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023381","descriptor_name":"Endpoint Determination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053208","descriptor_name":"Kaplan-Meier Estimate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.ejca.2014.03.012","doi":"https://doi.org/10.1016/j.ejca.2014.03.012","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2014.03.012","pdf_url":"http://www.ejcancer.com/article/S095980491400255X/pdf","source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},{"id":"pmid:24768571","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24768571","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of cancer (Oxford, England : 1990)","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1016/j.ejca.2014.03.012","doi":"https://doi.org/10.1016/j.ejca.2014.03.012","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejca.2014.03.012","pdf_url":"http://www.ejcancer.com/article/S095980491400255X/pdf","source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.6299999952316284,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2014417704.pdf","grobid_xml":"https://content.openalex.org/works/W2014417704.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W1521811891","https://openalex.org/W1545207088","https://openalex.org/W1571146896","https://openalex.org/W1979300931","https://openalex.org/W1992471607","https://openalex.org/W2008142406","https://openalex.org/W2010631330","https://openalex.org/W2040650599","https://openalex.org/W2063648710","https://openalex.org/W2073700732","https://openalex.org/W2099088585","https://openalex.org/W2100669312","https://openalex.org/W2101277591","https://openalex.org/W2118677643","https://openalex.org/W2137131274","https://openalex.org/W2149456801","https://openalex.org/W2153867442","https://openalex.org/W2154399935","https://openalex.org/W2155012968","https://openalex.org/W2155949904","https://openalex.org/W2158679766","https://openalex.org/W2160476851","https://openalex.org/W2161664263","https://openalex.org/W2162424705","https://openalex.org/W2166396356","https://openalex.org/W2167310266","https://openalex.org/W2167422856","https://openalex.org/W2328012298","https://openalex.org/W2750608157","https://openalex.org/W3010644992","https://openalex.org/W4229592104","https://openalex.org/W4293241248","https://openalex.org/W6774802734"],"related_works":["https://openalex.org/W2065621388","https://openalex.org/W1522297249","https://openalex.org/W2283641106","https://openalex.org/W7214232150","https://openalex.org/W2066063595","https://openalex.org/W1545207088","https://openalex.org/W2117559247","https://openalex.org/W2946656097","https://openalex.org/W3025389819","https://openalex.org/W2063648710"],"abstract_inverted_index":{"BACKGROUND:":[0],"To":[1],"determine":[2,97],"suitability":[3],"of":[4,106,125,146,155],"progression-free":[5],"survival":[6,14,51],"(PFS)":[7],"as":[8,81,221],"a":[9,40,82,110,222,237],"surrogate":[10,83,223],"end-point":[11,224],"for":[12,84,119,182,225],"overall":[13],"(OS),":[15],"we":[16],"evaluated":[17],"the":[18,53,137,165,179,183,228],"relationship":[19,46,194],"between":[20,47,55,66,197],"PFS":[21,48,56,67,78,100,129,142,162,171,185,198,218],"and":[22,49,57,68,74,103,178,199,232],"OS":[23,226],"in":[24,39,202,227],"750":[25],"treatment-na\u00efve":[26],"metastatic":[27],"renal":[28],"cell":[29],"carcinoma":[30],"(mRCC)":[31],"patients":[32,126,205],"who":[33],"received":[34],"sunitinib":[35,211],"or":[36,212],"interferon-alpha":[37],"(IFN-\u03b1)":[38],"phase":[41],"III":[42],"study.":[43],"METHODS:":[44],"The":[45,150],"post-progression":[50],"(PPS;":[52],"difference":[54],"OS)":[58],"was":[59,94,101,143,172,195],"studied,":[60],"which":[61],"correctly":[62],"removes":[63],"inherent":[64],"dependencies":[65],"OS,":[69],"to":[70,75,90,96,207,241],"properly":[71],"estimate":[72,242],"whether":[73,98],"what":[76],"extent":[77],"can":[79,219],"serve":[80],"OS.":[85],"A":[86,192],"Weibull":[87,138],"parametric":[88,139],"model":[89,151],"failure":[91],"time":[92],"data":[93],"fit":[95],"longer":[99,107,141,147,170,176],"significantly":[102,144,188],"meaningfully":[104],"predictive":[105,145],"PPS.":[108],"In":[109,136,164],"sensitivity":[111],"analysis":[112],"by":[113,128,132],"Kaplan-Meier":[114,166],"non-parametric":[115],"method,":[116],"PPS":[117,148,158,180,200,244],"curves":[118,181],"three":[120,184],"approximately":[121],"equal":[122],"numbered":[123],"groups":[124,186],"categorised":[127],"were":[130,187],"compared":[131],"log-rank":[133],"test.":[134],"RESULTS:":[135],"model,":[140],"(P<0.001).":[149],"also":[152,173],"allowed":[153],"prediction":[154],"estimated":[156],"median":[157,243],"duration":[159,201],"from":[160],"actual":[161],"times.":[163],"(non-parametric)":[167],"analysis,":[168],"incrementally":[169],"associated":[174],"with":[175,210,236],"PPS,":[177],"different":[189],"(P<0.0001).":[190],"CONCLUSIONS:":[191],"positive":[193],"found":[196],"individual":[203],"mRCC":[204,230],"randomised":[206],"first-line":[208,229],"treatment":[209],"IFN-\u03b1.":[213],"These":[214],"results":[215],"indicate":[216],"that":[217],"act":[220],"setting":[231],"provide":[233],"clinical":[234],"researchers":[235],"potentially":[238],"useful":[239],"approach":[240],"based":[245],"on":[246],"PFS.":[247]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}